|Bid||0.00 x 1400|
|Ask||0.00 x 1400|
|Day's Range||51.83 - 57.25|
|52 Week Range||37.00 - 85.40|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 31, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||96.05|
Subscribe to Yahoo Finance Plus to view Fair Value for IMABLearn more
I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first two patients have been dosed in the U.S. phase 2 dose expansion clinical study of its proprietary CD73 antibody uliledlimab (also known as TJD5) in combination with atezolizumab (Tecentriq®) in patients with ovarian cancer and other selected advanced or metastatic solid tumors.
Ascendis Pharma (ASND) is seeking approval for TransCon hGH for the treatment of pediatric growth hormone deficiency in Europe.
In this article, we reviewed Philip Best’s investment philosophy and portfolio management strategies. We also examined the top 10 stock picks of Philip Best’s Quaero Capital. You can skip our comprehensive list and detailed analysis and jump directly to the Top 5 Stock Picks of Philip Best’s Quaero Capital. Philip Best is the portfolio manager, […]